Home » Stocks » CVAC

CureVac N.V. (CVAC)

Stock Price: $102.69 USD 1.62 (1.60%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $101.25 -1.44 (-1.40%) Jan 22, 7:44 PM
Market Cap 18.28B
Revenue (ttm) 17.38M
Net Income (ttm) -102.42M
Shares Out 176.46M
EPS (ttm) -0.58
PE Ratio n/a
Forward PE 11.45
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $102.69
Previous Close $101.07
Change ($) 1.62
Change (%) 1.60%
Day's Open 100.05
Day's Range 99.11 - 103.25
Day's Volume 230,420
52-Week Range 43.80 - 136.27

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 1 week ago

CureVac shares currently trade at $100.6 - down from nearly $150 in early December. The mRNA specialist IPO'd at a price of just $16 in August last year, but shares have spiked in anticipation...

CNBC Television - 1 week ago

CureVac partners with Bayer to accelerate vaccine production

Franz-Werner Haas, CureVac CEO says it has initiated a phase 2b-3 trial and expects to enroll 35,000 people in Europe and Latin America. He joins 'Closing Bell' to discuss.

Other stocks mentioned: BAYRY
Accesswire - 1 week ago

Data provided further evidence on immunogenicity and protective efficacy of CVnCoV Induction of robust antibody and T cell responses at lower dose than tested in Phase 3 trial Full lung protec...

Zacks Investment Research - 2 weeks ago

CureVac (CVAC) gains on a collaboration agreement with Bayer (BAYRY) for further development and supply of its COVID-19 vaccine candidate, CVnCoV.

Other stocks mentioned: BAYRY
The Motley Fool - 2 weeks ago

The coronavirus vaccine developer announced a new partnership with a major player on the global pharmaceutical scene.

The Motley Fool - 2 weeks ago

Sometimes you need a little help from a big brother.

Other stocks mentioned: BAYRY
Benzinga - 2 weeks ago

CureVac BV (NASDAQ: CVAC) shares have received a nice lift and breached the $100 level for the first time in the new year. What Happened: German coronavirus vaccine maker CureVac said Thursday...

Other stocks mentioned: BAYRY
Schaeffers Research - 2 weeks ago

The shares of CureVac BV (NASDAQ:CVAC) are soaring this morning, up 18.5% at $102.88 at last check.

Other stocks mentioned: BAYRY
Business Wire - 2 weeks ago

LOS ANGELES--(BUSINESS WIRE)---- $CVAC #COVID19--Investor's Business Daily (IBD), a leading financial news and research organization, today announced its list of the 100 Best Companies of 2020...

Accesswire - 2 weeks ago

Companies enter into a collaboration and services agreement Bayer to support CureVac in numerous areas, including development and supply of CVnCoV CureVac benefits from Bayer's expertise and e...

Reuters - 2 weeks ago

German biotech firm CureVac has agreed to an alliance with drugmaker Bayer to get global support in seeking approval for its experimental COVID-19 vaccine and for distribution, the two compani...

Other stocks mentioned: BAYRY
Reuters - 2 weeks ago

German biotech firm CureVac has agreed to an alliance with drugmaker Bayer to get global support in seeking approval for its experimental COVID-19 vaccine and for distribution, daily Bild repo...

Other stocks mentioned: BAYRY
Accesswire - 1 month ago

Study to assess safety and immunogenicity of CVnCoV in high-risk population group Study builds on observational epidemiological study TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / December 2...

Zacks Investment Research - 1 month ago

Here we discuss four small biotech companies, NVAX, CVAC, VXRT and ARCT, that are making COVID-19 vaccine candidates, which may be approved in 2021, if successfully developed, and bring profits.

Other stocks mentioned: ARCT, NVAX, VXRT
Zacks Investment Research - 1 month ago

CureVac (CVAC) doses the first patient in a pivotal study on its COVID-19 vaccine candidate, CVnCoV. Shares rise following this development.

24/7 Wall Street - 1 month ago

CureVac N.V. (NASDAQ: CVAC) advanced in the fight against COVID-19 by beginning enrollment in its midstage vaccine candidate study.

Market Watch - 1 month ago

Tübingen-based CureVac said the Phase 3 trial will include more than 35,000 volunteers in Europe and Latin America

The Motley Fool - 1 month ago

If we judge by return on investment, these two mid-cap biotechs may be the ultimate winners of the coronavirus vaccine race.

Other stocks mentioned: NVAX
The Motley Fool - 1 month ago

Here's what you need to know about all of the leaders in the coronavirus vaccine race.

Other stocks mentioned: AZN, BNTX, JNJ, MRNA, NVAX, PFE
The Motley Fool - 1 month ago

And it's not too far behind coronavirus vaccine leaders Pfizer and Moderna.

Reuters - 2 months ago

The European Union could pay more than $10 billion to secure hundreds of millions of doses of the vaccine candidates being developed by Pfizer-BioNTech and CureVac, an EU official involved in ...

Other stocks mentioned: PFE
Bloomberg Markets and Finance - 2 months ago

Enough Pharma Capacity to Vaccinate World by End of 2021: CureVac CEO

Nov.18 -- CureVac Chief Executive Officer Franz-Werner Haas discusses the progress on the biopharmaceutical company's Covid-19 vaccine and scale-up for its production on “Bloomberg Surveillance.”

Market Watch - 2 months ago

CureVac expects to announce partnerships with vaccine developers and manufacturers in coming weeks to ramp up capacity of its potential vaccine candidate.

The Motley Fool - 2 months ago

Great efficacy results for mRNA COVID-19 vaccines so far could bode well for these three stocks.

Other stocks mentioned: ARCT, TBIO
The Motley Fool - 2 months ago

Biotech is on every investor's mind as we move closer and closer to a successful vaccine for the coronavirus. Here are three contenders for your portfolio.

Other stocks mentioned: BNTX, TSLA
Benzinga - 2 months ago

German biopharma CureVac BV (NASDAQ: CVAC) — which is developing an  mRNA vaccine against the novel coronavirus — was rallying Tuesday following the release of detailed interim Phase 1 data fo...

Market Watch - 2 months ago

Shares of CureVac gained 8.0% in premarket trading on Tuesday after the company disclosed additional clinical data about how its COVID-19 vaccine candidate is performing in a Phase 1 clinical ...

The Motley Fool - 2 months ago

Participants in the phase 1 clinical trial mounted an immune response after being inoculated with CVnCoV.

Investors Business Daily - 2 months ago

Recent hot IPO CureVac reported positive Phase 1 clinical trials data for its Covid-19 vaccine candidate, which is among a number based on mRNA technology. CVAC stock rose on the news.

Market Watch - 2 months ago

German biotech CureVac said advanced clinical trials are on track to launch by the end of 2020.

The Motley Fool - 2 months ago

The World Health Organization is managing a global vaccine program without U.S. participation, and it could have a big impact for investors.

Other stocks mentioned: AZN, BNTX, INO, JNJ, MRNA, NVAX, PFE
The Motley Fool - 3 months ago

CureVac is using the same messenger RNA approach that Moderna uses. Why is Moderna getting all the headlines?

The Motley Fool - 3 months ago

There's little doubt that COVID-19 vaccines will save many lives, but that doesn't mean investors will be rewarded.

Other stocks mentioned: AZN, BNTX, GSK, JNJ, MRNA, NVAX, PFE, SNY
The Motley Fool - 3 months ago

In the race for a vaccine, a pause in progress sets you back.

Other stocks mentioned: ALT, VBIV
The Motley Fool - 3 months ago

These companies made an early splash, but that doesn't mean they're a safe choice for investors.

Other stocks mentioned: GDRX, SNOW
Zacks Investment Research - 3 months ago

CureVac (CVAC) doses the first patient in a phase IIa study on its COVID-19 vaccine candidate CVnCoV. Shares rise in after-hours trading following this development.

InvestorPlace - 3 months ago

CureVac just announced it was launching Phase 2 trials in Peru and Panama for its coronavirus vaccine. CVAC stock is rallying in response.

Investors Business Daily - 3 months ago

Regeneron Pharmaceuticals stock rose on positive data on its possible Covid-19 treatment, while shares of Moderna and CureVac stock rose as their possible Covid-19 vaccines made advances. The ...

Other stocks mentioned: MRNA, REGN
InvestorPlace - 4 months ago

CureVac recently was awarded $299 million to support the development of its Covid-19 vaccine. What does this mean for CureVac stock?

The Motley Fool - 4 months ago

These two stocks have made shareholders rich in a very short amount of time. Here's why new potential investors should stay away.

Other stocks mentioned: SNOW
The Motley Fool - 4 months ago

BioNTech and CureVac will use the new funding to advance COVID-19 research and development in Germany.

Other stocks mentioned: BNTX
InvestorPlace - 4 months ago

Whether or not we get an 'October Surprise' from President Donald Trump, these coronavirus vaccine stocks look hot now. AstraZeneca (NYSE:AZN) CureVac (NASDAQ:CVAC) GlaxoSmithKline (NYSE:G...

Other stocks mentioned: AZN, GSK, INO, JNJ, MRNA, NVAX
InvestorPlace - 4 months ago

With its Covid-19 vaccine candidate, CureVac stock soared after its IPO in August. But as Operation Warp Speed wraps up, investors may wonder if there's anything else.

The Motley Fool - 4 months ago

Here are the answers to your top questions about where things stand with the development of COVID-19 vaccines.

Other stocks mentioned: AZN, BNTX, INO, JNJ, MRNA, NVAX, PFE
The Motley Fool - 4 months ago

Investors should exercise caution before buying into these high-flying growth stocks.

Other stocks mentioned: TDOC, VEEV
InvestorPlace - 4 months ago

CVAC stock is one of many intriguing plays on a Covid-19 vaccine. But 300% above the IPO price, investors seemingly have better options.

InvestorPlace - 4 months ago

Amid a sea of red ink in the Covid-19 vaccine space, CureVac stock has gone against the grain, printing some sizable gains. Can investors trust the momentum for CureVac?

The Motley Fool - 4 months ago

Late to the rally in coronavirus vaccine stocks? Consider these four rising biotechs.

Other stocks mentioned: DVAX, SRNE, VXRT
The Motley Fool - 4 months ago

That money will also be used for its production.

InvestorPlace - 4 months ago

Recent IPO and vaccine play CureVac stock could bounce back – but tread carefully. Much of the upside remains priced into shares.

About CVAC

CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its lead proprietary programs include CV8102 that is in a Phase 1 dose escalating clinical trials for four types of cancers as a monotherapy and in combination with anti-PD-1; and CV7202, which is in a Phase 1 clinical trials as a vaccine candidate against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase 1 clinical trial. The company's pa... [Read more...]

Industry
Biotechnology
IPO Date
Aug 14, 2020
CEO
Dr. Franz-Werner Haas L.L.M., Ph.D., LL.M.
Employees
500
Stock Exchange
NASDAQ
Ticker Symbol
CVAC
Full Company Profile

Financial Performance

In 2019, CureVac's revenue was $17.42 million, an increase of 35.31% compared to the previous year's $12.87 million. Losses were -$99.87 million, 40.2% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for CureVac stock is "Buy." The 12-month stock price forecast is 73.36, which is a decrease of -28.56% from the latest price.

Price Target
$73.36
(-28.56% downside)
Analyst Consensus: Buy